EC Number   |
Application |
Reference |
|---|
    2.4.2.8 | analysis |
the branched bi-enzyme system with xanthine oxidase is an important biochemical system to evaluate the efficiency of the anticancer drug 6-mercaptopurine, overview |
675050 |
| 2.4.2.8 | biotechnology |
genetic tools for use in Clostridium thermocellum that allow creation of unmarked mutations while using a replicating plasmid. The strategy employs counter-selections developed from the native Clostridium thermocellum hpt gene and the Thermoanaerobacterium saccharolyticum tdk gene and is used to delete the genes for both lactate dehydrogenase (Ldh) and phosphotransacetylase (Pta) |
-, 735482 |
| 2.4.2.8 | diagnostics |
there is other evidence of salvage enzymes serving as diagnostic and prognostic biomarkers to diagnose and monitor cancer development in patient. Evaluation of enzymes, including HPRT, APRT, and DCK, as potential biomarkers for colorectal cancer (CRC). Colorectal cancer cell lines SW-480, SW-620, and HT-29 have statistically significant HPRT expression on the surface of the cells, while Colo-205 cells show no significant increase in the surface presence of HPRT. Analysis within malignant colon samples confirms the variable nature of HPRT surface localization within patients |
759769 |
| 2.4.2.8 | drug development |
hypoxanthine-guanine phosphoribosyltransferase is an excellent target for antimalarial drug discovery |
758563 |
| 2.4.2.8 | drug development |
structural differences between the Tbr and human enzymes suggest that selective inhibitors for the Tbr enzyme can be designed. Crystal structures of the enzyme in complex with GMP and IMP and with three acyclic nucleoside phosphonate (ANP) inhibitors are determined. Differences occur between the diphosphate binding loops in human HGPRT and TbrHGPRT |
760143 |
| 2.4.2.8 | drug development |
the enzyme is a possible target for anti-parasite drug development |
758845 |
| 2.4.2.8 | drug development |
the enzyme is a target for antimalarial inhibitor design and development |
705041 |
| 2.4.2.8 | drug development |
the hypoxanthineguanine phosphoribosyltransferase (HGPRT) represents a potential target for specific inhibitor development |
-, 759433 |
| 2.4.2.8 | medicine |
potential target for antiparasitic chemotherapy |
638404, 638409, 638414, 638417, 638419, 638420 |
| 2.4.2.8 | medicine |
prospective pharmacodynamic study to determine the effect of combination therapy for treatment of inflammatory bowel disease on the activity of hypoxanthine-guanine phosphoribosyltransferase, which activates of thiopurine prodrugs to thioguanine nucleotides. The activity of hypoxanthine-guanine phosphoribosyltransferase and thioguanine nucleotides concentrations was measured in red blood cells during thiopurine monotherapy and after 4 weeks of combination therapy. The activity of hypoxanthine-guanine phosphoribosyltransferase was also measured after 12 weeks of combination therapy. Combination therapy increases the activity of hypoxanthine-guanine phosphoribosyltransferase and subsequently thioguanine nucleotides concentrations |
723304 |
